Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Benitec Biopharma Inc.

Benitec Biopharma Inc. develops a combination of gene therapy and RNA interference (gene silencing) to change treatment paradigms of human disease.

COM:BENITEC

Benitec Biopharma Inc.

Last Close

10.20

22/11 21:00

Market Cap

89.46M

Beta: -

Volume Today

22.17K

Avg: -

Financials Not Available